Results 41 to 50 of about 3,904 (178)

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil [PDF]

Anais Brasileiros de Dermatologia
: Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. Objective: The authors
Tania F. Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V.E. Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M. Soliman, Tianshuang Wu, Ranjeeta Sinvhal, Vassilis Stakias, Alexandra P. Song, Jasmina Kalabic, Naomi Martin, Luiza Keiko Matsuka Oyafuso   +16 more
doaj   +1 more source

Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia

Cost Effectiveness and Resource Allocation, 2023
Background Psoriasis, an immune-mediated chronic inflammatory disease primarily affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with chronic plaque psoriasis being the most common.
Yazed AlRuthia, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh, Majed Ali Almasaoud   +8 more
doaj   +1 more source

Update on risankizumab for the treatment of moderate to severe psoriasis [PDF]

, 2020
Introduction: The therapeutic landscape for psoriasis is ever-changing. Risankizumab is the newest approved biologic and one of three currently licensed that targets the p19 subunit of interleukin-23 (IL-23).
Al-Janabi, A; id_orcid, Warren, RB
core   +1 more source

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study [PDF]

, 2023
INTRODUCTION: Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD.
Tada, Yayoi, Liu, Jie, Messina, Izabella, Tyring, Stephen K, Beeck, Stefan, Rich, Phoebe, Huang, Xiaohong, Shumack, Stephen   +7 more
core   +2 more sources

Open-label extension of a phase 2 trial of risankizumab in patients with moderate-to-severe Crohn's disease [PDF]

, 2018
Background: Risankizumab, an anti-interleukin-23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn’s disease.

core   +2 more sources

Risankizumab versus ustekinumab for plaque psoriasis:a critical appraisal [PDF]

, 2019
Aim: Gordon et al investigated the efficacy and safety of risankizumab (an anti-interleukin[IL]23p19 biologic) compared with ustekinumab (anti-IL12/23p40) and placebo in patients with moderate-to-severe chronic plaque psoriasis.
Al-Janabi, A., Yiu, Z. Z. N., Yiu, Zenas; id_orcid, Al-Janabi, Ali; id_orcid, Jabbar-Lopez, Z. K., Jabbar-Lopez, Zarif, Griffiths, C. E. M.   +6 more
core   +1 more source

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. [PDF]

, 2021
peer reviewedBACKGROUND AND AIMS: Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn's disease.
Kaser, Arthur, Lee, W.J., Kalabic, Jasmina, Ferrante, Marc, Pang, Yinuo, Baert, F., Liao, Xiaomei, Kaser, A., D'Haens, Geert R, Panés, J., Louis, E., Duan, W Rachel, Baert, Filip, Duan, W. Rachel, Gustafson, Dawn, Feagan, Brian G., Wallace, Kori, Wallace, K., Liao, X., Lee, Wan-Ju, Duan, W.R., Louis, Edouard, D'Haens, G.R., D'Haens, Geert R., Panés, Julián, Feagan, Brian G, Dewit, Olivier, Gustafson, D., Feagan, B.G., Dewit, O., Pang, Y.   +30 more
core   +1 more source

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Acta Dermato-Venereologica, 2021
Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis.
Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo , Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo   +11 more
doaj   +1 more source

Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE [PDF]

Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life.
Nevena Skroza, Papini, Manuela, Gianmario Addis, Concetta Potenza, Riccardo Balestri, Nicoletta Bernardini, Maria A Montesu, Pierluigi Bruni, Montesu, Maria A, Megna, Matteo, Antonio Carpentieri, Bernardini, Nicoletta, Martino Carriero, Balestri, Riccardo, Sara Cacciapuoti, Laura Atzori, Atzori, Maria G, Michela Ortoncelli, Mugheddu, Cristina, Maria G Atzori, Ortoncelli, Michela, Addis, Gianmario, Atzori, Laura, Carriero, Martino, Rech, Giulia, Carpentieri, Antonio, Bruni, Pierluigi, Potenza, Concetta, Manuela Papini, Matteo Megna, Skroza, Nevena, Cristina Mugheddu, Giulia Rech, Cacciapuoti, Sara   +33 more
core   +1 more source

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study [PDF]

, 2022
ObjectivePsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA ...
Papp, Kim, Lars Erik Kristensen, Ann Eldred, White, Douglas, Soliman, Ahmed M., Keiserman, Mauro Waldemar, Eldred, Ann K., Barcomb, Lisa M., Lisa Barcomb, White, Douglas H.N., Lu, Wenjing, Papp, Kim A., Eldred, Ann, Ahmed M Soliman, Barcomb, Lisa, Mccasland, Leslie, Keiserman, Mauro, Leslie McCasland, McCasland, Leslie D., Wenjing Lu, Frank Behrens, Behrens, Frank, Kim Papp, Douglas White, Mauro Keiserman, Kristensen, Lars Erik   +25 more
core   +1 more source